{"data":{"type":"company_profile","id":198868,"entity_id":"wefunder:company:198868","attributes":{"canonical_url":"https://wefunder.com/axiombiosciences","generated_at":"2026-11-02T04:40:36Z","updated_at":"2026-11-02T04:36:03Z","entity_ids":{"company":"wefunder:company:198868","slug":"wefunder:company_slug:axiombiosciences"},"profile_visibility":{"owner_published":true,"public_search_results":true,"site_search_listed":true,"privacy_mode":"promote","invite_only":false},"provenance":{"source":"wefunder_public_company_profile","as_of":"2026-11-02T04:40:36Z","claims":{"total_amount_raised":{"source":"FrontCompanySummary#amount_raised","last_verified_at":"2026-11-02T04:36:03Z","as_of":"2026-11-02T04:40:36Z","confidence":"high"},"total_investors":{"source":"FrontCompanySummary#number_of_investors","last_verified_at":"2026-11-02T04:36:03Z","as_of":"2026-11-02T04:40:36Z","confidence":"high"},"active_raise_states":{"source":"Fundraise.visible(nil, nil)","last_verified_at":"2026-10-27T18:58:42Z","as_of":"2026-11-02T04:40:36Z","confidence":"high"},"latest_fundraise_state":{"source":"Fundraise.visible(nil, nil).order(funding_started_at)","last_verified_at":"2026-10-27T18:58:42Z","as_of":"2026-11-02T04:40:36Z","confidence":"medium"}}},"company":{"id":198868,"entity_id":"wefunder:company:198868","slug":"axiombiosciences","name":"Axiom Biosciences","tagline":"Precision regenerative therapies for brain injury. IPO ahead","story":"Axiom Biosciences is the world’s leading clinical-stage biotech company developing regenerative therapies for brain injury, starting with newborns and stroke survivors.Every year, millions of people suffer brain injury with no real path to recovery. Premature babies are often born with brain bleeds. Adults have their lives turned upside down by stroke. No treatment has ever given these patients a real chance at reclaiming their lost cognitive and motor function - until Axiom.Our lead therapy has eliminated mortality in newborns with Intraventricular Hemorrhage (IVH) and improved their neurologic function in clinical trials. Now, we're bringing that same platform to stroke, one of the leading causes of death and disability in the US.We've raised $21M+ in aggregate from VCs and won 8 federal grants from the National Institutes of Health (NIH), the California Institute for Regenerative Medicine (CIRM), and the Department of Defense, and have 50+ patents issued or pending. Our technology targets a $16.6B U.S. market for neonatal brain injury and stroke, with 7+ years of FDA market exclusivity.Backed by top-tier biotech VCs like Partners Investment, Proxima Ventures, Gemseki, Creative Ventures, Wilson Sonsini and KreaMedica, and with a public listing on the horizon, we are closer than medicine has ever been to giving damaged brains a chance to heal.In a clinical trial for Intraventricular Hemorrhage (IVH) in newborns, Axiom’s lead asset, AX-007 reduced mortality from brain bleeds by ~46% – every child treated showed improved functional neurologic parameters.Our second lead asset, AX-008, demonstrated equally compelling results in newborns with Hypoxic Ischemic Encephalopathy (HIE), reducing brain damage biomarkers, eliminating cerebral palsy, and reducing developmental delay in every treated child.While most biotech companies take years to land their first federal grant, we've won eight in just 3 years from the National Institutes of Health, California Institute for Regenerative Medicine, and the Department of Defense. This puts us in the top 2% of applicants and signals strong validation from the field's most rigorous scientific reviewers.The FDA has granted us two Rare Pediatric Disease Designations and two Orphan Disease Designations, giving us access to two Priority Review Vouchers (PRVs) valued at an estimated $400M - entirely non-dilutive to investors.We're targeting a Hong Kong Stock Exchange listing at a valuation of $1B+ in Q2 2027, the first step toward our eventual move to Nasdaq.With human data in hand, an estimated $400M in non-dilutive value from pending Priority Review Vouchers, and a $1B+ public listing ahead (not guaranteed), we're democratizing pre-IPO access for everyday investors.Brain damage doesn't discriminate; it strikes premature infants in NICUs and adults rebuilding their lives after a stroke.Each year, about 11,000 newborns are diagnosed with Intraventricular Hemorrhage or Hypoxic Ischemic Encephalopathy. There are no approved therapies. Without intervention, mortality rates can reach 66%, and survivors often face severe, lifelong disability.Stroke hits even harder at scale, affecting over 807,000 Americans annually, making it the leading cause of long-term disability in the country. Worldwide, roughly 12 million people suffer a stroke each year, and stroke ranks as the second leading cause of death globally. Current treatments can't regenerate damaged brain tissue, and patients are left to manage the aftermath.For decades, medicine has focused on managing damage rather than reversing it, because reversing it was not possible.Stem cells are the backbone of regenerative medicine, but there is a problem with how they translate their therapeutic value into humans. Stem cells naturally go to and repair inflamed tissues. In most humans, stem cells must decipher hundreds of inflammatory signals.Most competitors in the field are delivering unmodified cells through an intravenous (IV) route of administration and hope for the best, leaving the stem cell without a clear destination in the body. Worse, in the organ they are intended to treat, a very small percentage of cells ever get there to do the work because they are “diluted” into other organs, leading to a subpar therapeutic effect.Axiom takes a fundamentally different approach to stem cell therapy. We precondition every stem cell before it enters the body, programming each one with a specific mission – like setting a GPS before a road trip. Rather than administering cells through IV delivery, we deliver them directly into the brain via injection, ensuring 100% of the therapy reaches its target instead of dispersing through the bloodstream to the liver, spleen, or kidneys.Our stem cells are sourced exclusively from umbilical cords (aka Wharton Jelly Mesenchymal Stem Cells or WJ-MSC), the youngest and purest stem cells available, harvested at birth from healthy newborns. This matters because bone marrow and fat-derived stem cells come from adult donors, placental cells are a mixture of maternal and baby cells, and iPSC-derived cells are a mixed bag that is difficult to manufacture consistently.The biological mechanisms of brain injury in premature newborns with Intraventricular Hemorrhage (IVH) and Hypoxic Ischemic Encephalopathy (HIE) are similar to those caused by Ischemic and Hemorrhagic Stroke in adults, respectively, which means our platform can address four diseases with one manufacturing process and one delivery method.Axiom's lead is not a single advantage – it’s a stack. Our unlimited supply contract for umbilical cord stem cells gives us a manufacturing foundation no competitor can easily replicate. We have 50+ patents pending and 9 issued globally. Two FDA Rare Pediatric Disease Designations and two Orphan Disease Designations secure 7+ years of market exclusivity, protecting an estimated $4.7B in cumulative revenues from our lead assets.Unlike other biotech campaigns raising from the community, we already have real human clinical data. We are not asking investors to bet on a hypothesis. We have treated patients, measured outcomes and demonstrated the therapy works in humans.That's also why we're raising now, ahead of full commercialization: the capital funds this last stretch, where the science risk is lowest and the capital need is highest. And investors don't have to wait for product revenue to see a return: the two Priority Review Vouchers can be sold or licensed as soon as we reach approval.Dr. Ballantyne is a partner at Kineticos Disruptor Fund, a life sciences investment firm built specifically to back disruptive cell and gene therapies in neuroscience and rare disease, the exact category Axiom's platform sits in.Our core team brings executive experience from Stanford, Cornell, Yale, NYU, and the University of Michigan, with track records spanning landmark FDA trials, peer-reviewed publications in Nature Medicine, Blood, and PNAS, and C-suite leadership across biotech, legal, and multi-state retail operations.Behind them sits a scientific advisory board from Duke, NYU, Ohio State University, and City of Hope, with the backing of Johnson \u0026amp; Johnson Innovation Labs, one of the most influential innovation networks in global biopharma.Axiom's precision regenerative platform targets two of the most underserved conditions in neurology: neonatal brain damage, and stroke in adults. Together, these conditions represent a $16.6B annual total addressable therapeutic market in the US. Neither condition has an approved regenerative treatment.As a therapeutics company, Axiom sells its regenerative therapies to hospitals and health systems, who administer them to patients and are reimbursed by insurers, the standard commercial path for specialty cell therapies. With a first-in-class, best-in-class platform, we also expect to partner with a larger pharma company to scale distribution once we reach commercial launch.Axiom projects peak sales by year five of commercial launch of each of our four assets, sold through the hospital and health-system channel established above, from a single manufacturing process, providing us economies of scale. Year one projections start at $32M for AX-007 (IVH) alone, scaling past $551M by year five as market penetration grows across neonatal and stroke indications.As that penetration continues to mature beyond year five, peak annual gross profit across both indications reaches an estimated $4B+.With 87% gross margins on neonatal (IVH and HIE) and 46% gross margins on stroke (ischemic and hemorrhagic), every additional patient treated adds significant margin at minimal incremental cost.Brain injury was our first problem to solve, using the technologies we've built over the past seven years. Next, AX-011 extends our stem cell engineering platform, already funded by an active Department of Defense grant, from brain tissue to burns. AX-012, AX-013, and AX-014 all come from the same AI drug-design platform, the engine behind our lead assets' preclinical targeting, applied to atopic dermatitis, autoimmune disease, and cancer vaccines. These four programs use two of Axiom's existing platforms to reach new issues and diseases.We're going public in Hong Kong first because that's where the capital and the partners already are. The exchange has a long history of biotech listings and a mature investor base with strong appetite for clinical-stage science.Forward-looking statements are not guaranteed.Our lead therapy program was also co-developed with Medinno, based in South Korea, so a Hong Kong listing keeps us close to clinical partners already advancing our platform. Going public on the HKSE first and targeting NASDAQ listing later is a deliberate sequence: build value in a market built for Axiom, then bring that momentum stateside.This sequence works because the underlying science already holds up and the market and regulatory pathway are already validated.Mesoblast recently became the first company to win FDA approval for a stem cell therapy, achieving a market cap of $1.9B+ on a single FDA-approved stem cell therapy, only treating roughly 400 pediatric patients per year. Axiom's addressable patient population is 27x larger, spanning four diseases with one manufacturing process and human clinical data already in hand.Acquirers are already paying premiums for regenerative-therapy platforms before they reach commercialization. UCB recently agreed to acquire Neurona Therapeutics, a nervous system cell therapy company, for up to $1.2B — before Neurona reached commercialization. Axiom is further along, with more indications and stronger clinical proof.Future projections cannot be guaranteed.Every year, thousands of newborns face a brain bleed with a 46% mortality rate and no approved treatment. In our clinical trial, Axiom brought that number to zero in every child treated. We're now advancing the same platform toward stroke, a condition that affects over 800,000 Americans a year, with encouraging early results already in hand.Most biotech companies raise money from a handful of large investors, venture funds and institutional players. We're raising differently by opening this round to everyone, because the people whose support helps bring a therapy like this to market shouldn't be limited to a select few.Investing in Axiom means getting a direct stake in a company on a defined path to a public listing that has treated patients and measured actual outcomes.Invest in Axiom Biosciences today wefunder.com/axiombiosciences/invest.","location":"San Diego, CA","website":"https://axiombio.co","total_amount_raised":673616,"total_investors":58,"is_funded":false,"is_active":true,"quality_score":4,"related_urls":["https://wefunder.com/axiombiosciences","https://axiombio.co"]},"media":{"share_image_url":"https://uploads.wefunder.com/uploads/company/header_media_photo/198868/xxl_avatar.jpg","logo_url":"https://uploads.wefunder.com/uploads/company/logo/198868/large_avatar.jpg","header_media_url":"https://uploads.wefunder.com/uploads/company/header_media_photo/198868/standard_avatar.jpg","cover_photo_url":"https://uploads.wefunder.com/uploads/company/header_media_photo/198868/standard_avatar.jpg","pitch_deck_url":"https://wefunder.com/rails/active_storage/blobs/redirect/eyJfcmFpbHMiOnsiZGF0YSI6MjE5MzQ5NCwicHVyIjoiYmxvYl9pZCJ9fQ==--392713bbd9c9bab07bebb2d62b2b706327a5ea1b/Democratized%20Crossover%20Investor%20Presentation%20Final%20090126.pptx","pitch_deck_filename":"Democratized Crossover Investor Presentation Final 090126.pptx"},"links":{"company_url":"https://axiombio.co"},"highlights":[{"id":62781,"name":"venture_backed","url":"venturebacked","presentable_name":"VC-Backed","description":"Raised $250K or more from a venture firm","image_url":"https://uploads.wefunder.com/2021/profile-highlights-check.svg"},{"id":75537,"name":"repeat_founder","url":"repeatfounder","presentable_name":"Repeat Founder","description":"Started a prior company with $2M+ in funding or revenue","image_url":"https://uploads.wefunder.com/2021/profile-highlights-replay.svg"}],"quick_facts":[{"index":1,"claim_id":"claim-fact-1","value":"First US biotech targeting Hong Kong listing at $1B+ (2027); Nasdaq at $3B+ (2029); not guaranteed"},{"index":2,"claim_id":"claim-fact-2","value":"In clinical trial for IVH (brain bleeds in newborns): mortality eliminated, from ~46% to 0%"},{"index":3,"claim_id":"claim-fact-3","value":"$21M raised from VCs like Partners Investment \u0026amp; Proxima Ventures \u0026amp; 8 grants (NIH, CIRM, DoD)"},{"index":4,"claim_id":"claim-fact-4","value":"Targeting a $16.6B annual market in the US with 7+ years of FDA market exclusivity"},{"index":5,"claim_id":"claim-fact-5","value":"50+ patents pending and 9 issued globally"},{"index":6,"claim_id":"claim-fact-6","value":"2 FDA Rare Pediatric Disease Designations \u0026amp; potential Priority Review Vouchers; est. $400M+ value"},{"index":7,"claim_id":"claim-fact-7","value":"2 FDA Orphan Disease Designations secure 7+ years of exclusivity, protecting $4.7B in revenue"},{"index":8,"claim_id":"claim-fact-8","value":"World-class team from Stanford, Cornell, Yale, NYU \u0026amp; Michigan, backed by J\u0026amp;J Innovation Labs"}],"team":[{"id":6636149,"entity_id":"wefunder:company_role:6636149","user_entity_id":"wefunder:user:5069048","role":"founder","name":"Remo Moomiaie","title":"Founder \u0026 CEO","bio":"Serial entrepreneur \u0026amp; investor. Co-founded, Zerigo Health. Raising $100M. GP, Inventa Capital ($50M AUM). 8 US govt. grants. Former Yale Surgical Resident. Board member, Alliance mRNA Medicines. SUNY Stony Brook BS, Univ. of Szeged MD.","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/6636149/square_avatar.jpg?1791402223","profile_url":"https://wefunder.com/remo.moomiaie","linkedin_url":"https://linkedin.com/in/remo-moomiaie-qajar-m-d-7bb4835/","related_urls":["https://wefunder.com/remo.moomiaie"]},{"id":6638450,"entity_id":"wefunder:company_role:6638450","user_entity_id":"wefunder:user:5070743","role":"employee","name":"Karen Markham","title":"Chief Administrative Officer","bio":"Operations architect. Americas rep, LEGO Intl. HR Strategy Team. COO, Robinson Donovan Law. VP Operations, largest ACE Hardware franchise; drove the most profitable years in the cooperative's 95-year history. Built Axiom's full operational backbone.","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/6638450/square_avatar.jpg?1791402223","profile_url":"https://wefunder.com/karen.markham","linkedin_url":"https://linkedin.com/in/karen-markham-103529231/","related_urls":["https://wefunder.com/karen.markham"]},{"id":6642572,"entity_id":"wefunder:company_role:6642572","role":"employee","name":"Luke Peterson, PhD","title":"Chief Scientific Officer","bio":"Research innovator. 30 years of biotech research; 12 at the Univ. of Michigan, Professor. Named investigator on active DoD-funded Axiom grant. 20+ peer-reviewed publications. Hogeschool van Utrecht Biochemistry BS. Univ. of Manchester Oncology PhD.","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/6642572/square_avatar.jpg?1791402223","linkedin_url":"https://linkedin.com/n/luke-peterson-a0334979/","related_urls":[]},{"id":6642227,"entity_id":"wefunder:company_role:6642227","user_entity_id":"wefunder:user:5073433","role":"employee","name":"Reem Yunis, PhD.","title":"Director of Clinical Development","bio":"Clinical trial strategist. 15+ years pre-IND through registrational trials. Led trial strategy at Medable, a $2.1B clinical trials company. $2M FDA-funded researcher. 20+ publications, 2 patents. Hebrew University Life Sciences BSc \u0026amp; Genetics PhD.","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/6642227/square_avatar.jpg?1791402223","profile_url":"https://wefunder.com/reem.yunis.phd","linkedin_url":"https://linkedin.com/reemyunis/","related_urls":["https://wefunder.com/reem.yunis.phd"]},{"id":6652658,"entity_id":"wefunder:company_role:6652658","role":"employee","name":"Yaming Wang, PhD","title":"Director of Asian Operations","bio":"Global growth driver. Scaled Alphabet Health to $8M+ revenue \u0026amp; 40+ employees across US, China, \u0026amp; Europe. Drove 82% revenue growth at Prime Global, a healthcare consultancy. 20+ publications. Nanjing University PhD \u0026amp; NYU Molecular Oncology PhD.","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/6652658/square_avatar.jpg?1791402223","linkedin_url":"https://linkedin.com/in/yaming-wang-6480713/","related_urls":[]}],"featured_investors":[{"id":13328,"entity_id":"wefunder:company_investor_profile:13328","investor_profile_id":4566398,"investor_profile_entity_id":"wefunder:investor_profile:4566398","subject_entity_id":"wefunder:notable_investor:17290","name":"John Ballantyne, PhD","role_title":"","bio":"Dr. John Ballantyne, PhD, is a biotech leader and co-founder of Aldevron, acquired by Danaher in 2021 for $9.6B. He is a Partner of Kineticos Disruptor Fund, investing in innovative biotechnology platform technology and contract manufacturing companies.","avatar_url":"https://wefunder.com/rails/active_storage/blobs/redirect/eyJfcmFpbHMiOnsiZGF0YSI6MTY1NzA2MCwicHVyIjoiYmxvYl9pZCJ9fQ==--2f32e832fbab8d5b59dedfb2f8e22a6e246d41cd/avatar.jpg","profile_url":"https://wefunder.com/john.ballantyne.phd","endorsement_quote":"The breadth of utility of the MSCs alone in the neurological space gives the Axiom advanced program portfolio an extreme upside. Moreover, manufacturing is scalable and de-risked. I have great confidence in Remo and the team to be able to execute and bring high value products to market.","endorsement_name":"","is_lead_investor":false,"related_urls":["https://wefunder.com/john.ballantyne.phd"]},{"id":13326,"entity_id":"wefunder:company_investor_profile:13326","investor_profile_id":4565876,"investor_profile_entity_id":"wefunder:investor_profile:4565876","subject_entity_id":"wefunder:notable_investor:17286","name":"Partners Investment","role_title":"Managing Director","bio":"Partners Investment is a Seoul-based VC/PE firm with ~27 years of experience and ~$1B AUM. It manages 8 funds (4 healthcare-focused) and ~70 global biotech companies, with a cross-border team spanning Korea, U.S., and China, investing across all stage.","avatar_url":"https://wefunder.com/rails/active_storage/blobs/redirect/eyJfcmFpbHMiOnsiZGF0YSI6MTY1Njk2MSwicHVyIjoiYmxvYl9pZCJ9fQ==--1b4884442179234a8a83323c531b4a0b38cf08c8/avatar.jpg","profile_url":"https://wefunder.com/partners.investment","endorsement_quote":"Axiom Biosciences exemplifies the breakthrough platforms we seek- innovative, clinically focused, and built for scale. The company has rapidly advanced with multi-clinical-stage assets in the pipeline with strong regulatory positioning. Axiom’s true strength lies in its leadership, Remo has built a world-class team with the vision and execution to translate cutting-edge science into impactful medicines that have shown to have meaningful outcomes for patients.","endorsement_name":"Jaeyeol An, PhD. ","is_lead_investor":false,"related_urls":["https://wefunder.com/partners.investment"]},{"id":13329,"entity_id":"wefunder:company_investor_profile:13329","investor_profile_id":4566413,"investor_profile_entity_id":"wefunder:investor_profile:4566413","subject_entity_id":"wefunder:notable_investor:17291","name":"Proxima Ventures","role_title":"Partner","bio":"Proxima Ventures is an international life science VC with 7 funds and $5B AUM. It has invested in 70+ companies across biopharma, medical devices, and life science tools.","avatar_url":"https://wefunder.com/rails/active_storage/blobs/redirect/eyJfcmFpbHMiOnsiZGF0YSI6MTY1NzA3MSwicHVyIjoiYmxvYl9pZCJ9fQ==--7fb93bbc97c2a6f91e28c28c46813ad59053d422/avatar.jpg","profile_url":"https://wefunder.com/proxima.vc","endorsement_quote":"We are early investor in the company, and the company's novel technology has broad applications.","endorsement_name":"Haolin Sung","is_lead_investor":false,"related_urls":["https://wefunder.com/proxima.vc"]},{"id":13327,"entity_id":"wefunder:company_investor_profile:13327","investor_profile_id":4566378,"investor_profile_entity_id":"wefunder:investor_profile:4566378","subject_entity_id":"wefunder:notable_investor:17289","name":"Gemseki Investment","role_title":"President and CEO","bio":"Gemseki Investment, SNBL’s corporate VC in Japan, combines capital with deep drug development expertise. It supports ~25 biotech companies and manages ~$70M AUM, providing regulatory, nonclinical, and strategic guidance.","avatar_url":"https://wefunder.com/rails/active_storage/blobs/redirect/eyJfcmFpbHMiOnsiZGF0YSI6MTY1NzAyMCwicHVyIjoiYmxvYl9pZCJ9fQ==--d7b9a33ce4a692ea9fde8c5810eef906c7ff9104/avatar.jpg","profile_url":"https://wefunder.com/gemseki","endorsement_quote":"What excites us most about our investment in Axiom is the significant progress the team has made with technologies that meaningfully expand the potential of cell therapy. Their approach addresses key limitations in the field and opens new possibilities for broader patient impact. Combined with a highly capable and focused team, we believe Axiom is well positioned to shape the future of cell-based therapeutics.","endorsement_name":"Yoshiharu Asanuma","is_lead_investor":false,"related_urls":["https://wefunder.com/gemseki"]},{"id":13330,"entity_id":"wefunder:company_investor_profile:13330","investor_profile_id":4566547,"investor_profile_entity_id":"wefunder:investor_profile:4566547","subject_entity_id":"wefunder:notable_investor:17293","name":"Inventa Capital","role_title":"General Partner","bio":"Inventa Capital (RMI LLC) is a multi Family Office which has invested in 14 early stage life science and enterprise tech companies since 2015 and has returned \u0026gt;150% to LPs on exits to date.","avatar_url":"https://wefunder.com/rails/active_storage/blobs/redirect/eyJfcmFpbHMiOnsiZGF0YSI6MTY1NzQ1NywicHVyIjoiYmxvYl9pZCJ9fQ==--149091ca4f3563c87893a211884276b644045f0b/avatar.jpg","profile_url":"https://wefunder.com/inventa.capital","endorsement_quote":"I’ll admit, it’s a bit unconventional to write an endorsement for a company I founded. But I’ve invested my own capital alongside our investors because I genuinely believe in what we’re building at Axiom, and importantly willing to take on risk with them (and you). We’re not only tackling some of the most challenging diseases, but also redefining what a focused, lean biotech can achieve. Most importantly, I have complete conviction in my team's ability to execute and deliver meaningful outcomes for both patients and investors.","endorsement_name":"Remo Moomiaie-Qajar, MD","is_lead_investor":false,"related_urls":["https://wefunder.com/inventa.capital"]}],"investor_memos":[],"tab_counts":{"posts":5,"ask_questions":1,"featured_investors":5,"faq_entries":1},"active_fundraises":[{"id":165087,"entity_id":"wefunder:fundraise:165087","state":"successful","offering_type":"4(a)(6)","funding_type":"note","structure":"ttw","security_type":"","currency":"USD","testing_the_waters":true,"min_purchase":250,"max_purchase":9,"funding_target":1000000.0,"minimum_target":"50000.0","maximum_target":"1000000.0"},{"id":165086,"entity_id":"wefunder:fundraise:165086","state":"open","offering_type":"4(a)(6)","funding_type":"note","structure":"equity","security_type":"equity","currency":"USD","testing_the_waters":false,"min_purchase":250,"max_purchase":9,"funding_target":1000000.0,"minimum_target":"50000.0","maximum_target":"1000000.0","funding_started_at":"2026-10-27T18:48:50Z","funding_closed_at":"2027-04-01T03:59:59Z"}],"latest_fundraise":{"id":165087,"entity_id":"wefunder:fundraise:165087","state":"successful","offering_type":"4(a)(6)","structure":"ttw","testing_the_waters":true,"can_invest_now":false,"funding_started_at":null,"funding_closed_at":null,"terms":{"eb":"$80M","nb":"$96M","txt":"pre-money valuation"}},"recent_posts":[{"id":378840,"entity_id":"wefunder:feed_item:378840","type":"FeedItem::Update","visibility":"public","title":"AI and drug development: Axiom live on CNBC! 🎥","preview":"We recently announced our plan to pursue a primary listing on the Hong Kong Stock Exchange in 2027, with a Nasdaq listing to follow in 2029. It's a milestone years in the making, and the response since has been incredible.🎉Along with the announcement came a wave of press, including an interview with CNBC.Check out the interview hereNaturally, one of the questions was about AI and I want to share with you a bit more about how AI fits into our strategy of developing next generation genetic medi...","published_at":"2026-09-04T15:07:53Z","author_name":"Remo Moomiaie","url":"/feed/378840","canonical_url":"https://wefunder.com/feed/378840"},{"id":376395,"entity_id":"wefunder:feed_item:376395","type":"FeedItem::Update","visibility":"public","title":"A million-dollar biotech deal just validated something we're sitting on 🧬","preview":"I want to share a piece of industry news from this week, because it says a lot about where Axiom is headed.Arrowhead Pharmaceuticals just signed a deal to acquire an FDA Priority Review Voucher, a designation that cuts a drug's FDA review time from ten months to six. Arrowhead plans to use it to speed the expanded approval of their approved therapy, REDEMPLO. The price was $215 million, with recent vouchers being sold for $150 million to over $200 million, including Jazz Pharmaceuticals' $200...","published_at":"2026-08-29T13:13:43Z","author_name":"Remo Moomiaie","url":"/feed/376395","canonical_url":"https://wefunder.com/feed/376395"},{"id":355527,"entity_id":"wefunder:feed_item:355527","type":"FeedItem::Update","visibility":"public","title":"📣​Breaking News: We're setting our sights on a Hong Kong IPO","preview":"I have some big news: we're targeting a Hong Kong IPO in 2027, with a NASDAQ listing to follow in 2029 🚀We’re the first American company to list on the Hong Kong stock exchange.This is a contrarian move for a U.S.-based biotech, and that's exactly why we're making it. Here are three reasons we chose this path:🔬 Hong Kong has built one of the most sophisticated biotech investor networks in the world. These are investors who understand the timelines, the risks, and the capital needs of next-gen...","published_at":"2026-07-22T22:06:58Z","author_name":"Remo Moomiaie","url":"/feed/355527","canonical_url":"https://wefunder.com/feed/355527"},{"id":356317,"entity_id":"wefunder:feed_item:356317","type":"FeedItem::Update","visibility":"public","title":"We are onto something big here!","preview":"Today we publicly announced our intent to list on the HKEX and take Axiom public. Three news outlets competed for the exclusive write of first print and first interview. At the end, we granted CNBC Asia the right to the interview and Bloomberg Asia to the first print. Many other media outlets have been interviewing Remo and here are some of the articles that went public today. The attention and interest in our story is exceptional! Lets' keep thing moving forward. Share this news and the link...","published_at":"2026-07-21T23:43:12Z","author_name":"Remo Moomiaie","url":"/feed/356317","canonical_url":"https://wefunder.com/feed/356317"},{"id":352404,"entity_id":"wefunder:feed_item:352404","type":"FeedItem::Update","visibility":"public","title":"Phase 1 Clinical Trial Results!","preview":"We're proud to share the positive Phase 1 results for our investigational stem cell therapy treating severe brain injury in newborns (IVH and HIE). All patients survived to 12 months, with significant gains in cognitive and motor outcomes.The study was three years in the making, and we couldn't be happier for the kids and families it's touched. We believe the same stem cell therapy could give meaningful improvements in other forms of brain injuries like stroke and traumatic brain injuries. ht...","published_at":"2026-07-14T12:58:23Z","author_name":"Remo Moomiaie","url":"/feed/352404","canonical_url":"https://wefunder.com/feed/352404"}],"q_and_a":[{"id":337190,"entity_id":"wefunder:comment:337190","question":"Could you share a bit more about the following? current valuation what I’d actually be investing in (share class) The expected dilution What you see as the key risks to the business over the next couple of years. Also… why HK?","author_name":"Meghan Cannarella","votes":0,"created_at":"2026-07-09T14:55:29Z","canonical_url":"https://wefunder.com/axiombiosciences#question-337190","answers":[{"id":337214,"entity_id":"wefunder:comment:337214","answer":"Hi Meghan, Thanks for the great questions. Axiom's current pre-money valuation is $80M. This isn't a conventional opportunity investment, we're extending part of our pre-IPO (aka Crossover) Round to retail investors. Technically you'd be investing in our Series A-2, but since this is our Crossover round (the final private raise before IPO), we don't expect to raise again before then, so no anticipated dilution. Key risk factors are in the attached document, please review them. On why HKEX: a few reasons make it the right strategic choice. First, unlike every other biotech listed on HKEX, we're not a Chinese company. Second, amid geopolitical tension in biopharma, we're aligned with the view that faster, more cost-efficient drug development wins. Third, HKEX-listed biotechs have outperformed the XBI and NASDAQ peers in 2025 that listed around the same time. HK enables us to build our companies pipeline both in depth and width. And finally, HKEX isn't an endpoint for us it's a step toward a future secondary listing. Our goal is to build a global, category-defining company, and we're willing to pioneer that path. Hope that answers your questions.","author_name":"Remo Moomiaie","votes":0,"created_at":"2026-07-09T17:42:37Z"}]}],"faq":[{"question":"Could you share a bit more about the following? current valuation what I’d actually be investing in (share class) The expected dilution What you see as the key risks to the business over the next couple of years. Also… why HK?","answer":"Hi Meghan, Thanks for the great questions. Axiom's current pre-money valuation is $80M. This isn't a conventional opportunity investment, we're extending part of our pre-IPO (aka Crossover) Round to retail investors. Technically you'd be investing in our Series A-2, but since this is our Crossover round (the final private raise before IPO), we don't expect to raise again before then, so no anticipated dilution. Key risk factors are in the attached document, please review them. On why HKEX: a ..."}]}}}